1 – 20 of 20
- show: 100
- |
- sort: year (new to old)
Close
Embed this list
<iframe src=" "
width=" "
height=" "
allowtransparency="true"
frameborder="0">
</iframe>
- 2023
-
Mark
Genetics of circulating inflammatory proteins identifies drivers of immune-mediated disease risk and therapeutic targets
(
- Contribution to journal › Article
- 2021
-
Mark
Mendelian randomisation identifies alternative splicing of the FAS death receptor as a mediator of severe COVID-19
2021)(
- Working paper/Preprint › Preprint in preprint archive
- 2017
-
Mark
Relations between lipoprotein(a) concentrations, LPA genetic variants, and the risk of mortality in patients with established coronary heart disease : A molecular and genetic association study
(
- Contribution to journal › Article
- 2015
-
Mark
High Plasma Levels of Heparin-Binding Epidermal Growth Factor Are Associated With a More Stable Plaque Phenotype and Reduced Incidence of Coronary Events.
(
- Contribution to journal › Article
- 2013
-
Mark
Large-scale association analysis identifies new risk loci for coronary artery disease
(
- Contribution to journal › Article
-
Mark
Discovery and refinement of loci associated with lipid levels
(
- Contribution to journal › Article
-
Mark
Common variants associated with plasma triglycerides and risk for coronary artery disease
(
- Contribution to journal › Article
- 2011
-
Mark
Relationship between clopidogrel-induced platelet P2Y12 inhibition and stent thrombosis or myocardial infarction after percutaneous coronary intervention-A case-control study
(
- Contribution to journal › Article
- 2010
-
Mark
Niemann-Pick C1 Modulates Hepatic Triglyceride Metabolism and Its Genetic Variation Contributes to Serum Triglyceride Levels
(
- Contribution to journal › Article
- 2009
-
Mark
Genetic variation of CYP2C19 affects both pharmacokinetic and pharmacodynamic responses to clopidogrel but not prasugrel in aspirin-treated patients with coronary artery disease
(
- Contribution to journal › Article
- 2008
-
Mark
Prasugrel achieves greater and faster P2Y12receptor-mediated platelet inhibition than clopidogrel due to more efficient generation of its active metabolite in aspirin-treated patients with coronary artery disease
(
- Contribution to journal › Article
-
Mark
Greater reduction of platelet activation markers and platelet-monocyte aggregates by prasugrel compared to clopidogrel in stable coronary artery disease
(
- Contribution to journal › Article
-
Mark
Patients with poor responsiveness to thienopyridine treatment or with diabetes have lower levels of circulating active metabolite, but their platelets respond normally to active metabolite added ex vivo.
(
- Contribution to journal › Article
- 2000
-
Mark
Binding of factor VIIa to tissue factor on human fibroblasts leads to activation of phospholipase C and enhanced PDGF-BB-stimulated chemotaxis
(
- Contribution to journal › Article
- 1999
-
Mark
Overactivation of phospholipase C-gamma1 renders platelet-derived growth factor beta-receptor-expressing cells independent of the phosphatidylinositol 3-kinase pathway for chemotaxis
(
- Contribution to journal › Article
- 1996
-
Mark
Structural determinants in the platelet-derived growth factor alpha-receptor implicated in modulation of chemotaxis
(
- Contribution to journal › Article
-
Mark
Mutation of a Src phosphorylation site in the PDGF beta-receptor leads to increased PDGF-stimulated chemotaxis but decreased mitogenesis
(
- Contribution to journal › Article
- 1994
-
Mark
A unique autophosphorylation site in the platelet-derived growth factor alpha receptor from a heterodimeric receptor complex
(
- Contribution to journal › Article
- 1993
-
Mark
Increased Kit/SCF receptor induced mitogenicity but abolished cell motility after inhibition of protein kinase C
(
- Contribution to journal › Article
- 1988
-
Mark
A glioma-derived PDGF A chain homodimer has different functional activities than a PDGF AB heterodimer purified from human platelets
(
- Contribution to journal › Article